Corporate Compliance Programs Now Accountable To “Two Agencies” – Pitt
This article was originally published in The Gray Sheet
Executive Summary
Device firms may need to become more proactive on Securities & Exchange Commission compliance issues under the agency's formal alliance with FDA on regulating investor communications
You may also be interested in...
FDA Centralizes Internal Procedure For SEC Communications
FDA's new process for referring information to the Securities & Exchange Commission could result in heightened CDRH attention to potentially false or misleading statements by device firms
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.